“The future of the European generic medicines industry is under serious threat, which places both the sustainability of European health care and the European industrial competitiveness at serious risk,” warned Mr Greg Perry, Director General of the European Generics medicines Association (EGA), at an EGA conference on healthcare sustainability on 31 March 2009 in Prague, Czech Republic.
- INICIO
-
Genéricos
Novedades
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
Investigación
- Evaluation of pharmaceutical equivalency of manufactured generic drugs in UAE
- New insights into the amount of R & D for new uses of generic drugs
- Pricing and reimbursement of medicines in Canada
- Medicines pricing conditions in Italy and Brazil: comparison of regulations
-
Biosimilares
Novedades
- Biosimilar launches in Canada and US: Byooviz and Stimufend
- EMA recommends approval of eculizumab biosimilar Bekemv
- China approves tocilizumab copy biological BAT1806
- FDA accepts application for denosumab biosimilar GP2411
Investigación
- Low biosimilar uptake in regions of low social and political trust
- A global overview of manufacturers of follow-on biologicals
- Study supports increased development of insulin biosimilars
- Perspectiva y papel de los farmacéuticos hospitalarios de Malasia en la promoción del uso de biosimilares
- MORE EDITORIAL SECTIONS
- Search
Post your comment